Last reviewed · How we verify
Mydriasert® insert
At a glance
| Generic name | Mydriasert® insert |
|---|---|
| Sponsor | Unither Pharmaceuticals, France |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacodynamics of a Fixed Dose Combination of 0.34% Tropicamide and 2.5% Phenylephrine Hydrochloride, Eye Drop, Solution (PHASE1, PHASE2)
- Efficacy Mydrane ® for Cataract Surgery in Patients With Concomitant Primary Open Angle Glaucoma. (NA)
- CLAIR -FO: Clinical Trial of Ophthalmic Insert Mydriasert® Versus Reference Treatment (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mydriasert® insert CI brief — competitive landscape report
- Mydriasert® insert updates RSS · CI watch RSS
- Unither Pharmaceuticals, France portfolio CI